To include your compound in the COVID-19 Resource Center, submit it here.

Perosphere, Daiichi Sankyo deal

Daiichi Sankyo will co-sponsor a Phase I trial evaluating Perosphere's PER977

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE